California State Teachers Retirement System grew its position in Acceleron Pharma Inc. (NASDAQ:XLRN) by 5.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,795 shares of the biopharmaceutical company’s stock after buying an additional 2,826 shares during the quarter. California State Teachers Retirement System owned 0.15% of Acceleron Pharma worth $1,726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of XLRN. Parametric Portfolio Associates LLC acquired a new stake in shares of Acceleron Pharma in the first quarter valued at $241,000. Teachers Advisors LLC grew its stake in shares of Acceleron Pharma by 2.1% in the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock valued at $1,220,000 after buying an additional 942 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of Acceleron Pharma by 25.7% in the first quarter. TIAA CREF Investment Management LLC now owns 98,743 shares of the biopharmaceutical company’s stock valued at $2,614,000 after buying an additional 20,189 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Acceleron Pharma by 9.1% in the first quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock valued at $50,619,000 after buying an additional 158,714 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Acceleron Pharma by 2.8% in the first quarter. Geode Capital Management LLC now owns 271,440 shares of the biopharmaceutical company’s stock valued at $7,185,000 after buying an additional 7,378 shares in the last quarter. 75.85% of the stock is owned by institutional investors and hedge funds.

Shares of Acceleron Pharma Inc. (XLRN) opened at $38.71 on Friday. Acceleron Pharma Inc. has a fifty-two week low of $23.07 and a fifty-two week high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. Acceleron Pharma’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.55) EPS. equities research analysts anticipate that Acceleron Pharma Inc. will post -2.67 EPS for the current year.

In other news, SVP Christopher Rovaldi sold 14,000 shares of Acceleron Pharma stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total transaction of $537,740.00. Following the sale, the senior vice president now owns 28,232 shares in the company, valued at $1,084,391.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Corp /De/ Celgene bought 745,592 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were purchased at an average price of $37.00 per share, for a total transaction of $27,586,904.00. Following the transaction, the insider now directly owns 6,118,479 shares of the company’s stock, valued at approximately $226,383,723. The disclosure for this purchase can be found here. Insiders have sold a total of 53,513 shares of company stock valued at $2,055,485 over the last ninety days. 3.90% of the stock is owned by company insiders.

A number of brokerages have recently weighed in on XLRN. Zacks Investment Research lowered Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. BidaskClub lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday. HC Wainwright lifted their target price on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Finally, Credit Suisse Group set a $35.00 target price on Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.88.

COPYRIGHT VIOLATION WARNING: “California State Teachers Retirement System Raises Stake in Acceleron Pharma Inc. (XLRN)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/18/california-state-teachers-retirement-system-raises-stake-in-acceleron-pharma-inc-xlrn.html.

Acceleron Pharma Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.